Residency · Residency · Radiation Oncology

Limited-Stage Small Cell Lung Cancer: Twice-Daily vs. Once-Daily Radiation

Overview

Small cell lung cancer (SCLC) accounts for approximately 13-15% of all lung cancers and is characterized by a rapid doubling time, early dissemination, and a high initial sensitivity to chemotherapy. Limited-stage (LS) disease is defined as cancer confined to one hemithorax and regional lymph nodes that can be encompassed within a single radiation field, roughly corresponding to stage I-III disease. The standard treatment for LS-SCLC involves concurrent chemoradiation, typically with cisplatin and etoposide. With optimal treatment, the 5-year overall survival (OS) rate is approximately 25-30%. Twice-daily (BID) radiation, delivering 45 Gy in 30 fractions at 1.5 Gy twice daily, was established as a standard regimen by the Turrisi trial. However, once-daily higher-dose regimens ranging from 60 to 70 Gy are also commonly used. Prophylactic cranial irradiation (PCI) has been a standard component of therapy to reduce brain metastases, but its role is currently being reassessed in the era of MRI surveillance.

Landmark Clinical Trials

Turrisi et al. (1999) -- INT 0096

The Turrisi trial was a phase III study comparing 45 Gy delivered once daily in 25 fractions (1.8 Gy per fraction over 5 weeks) versus 45 Gy delivered twice daily in 30 fractions (1.5 Gy twice daily over 3 weeks), both given concurrently with cisplatin and etoposide chemotherapy. The twice-daily arm demonstrated a significant improvement in 5-year OS, with 26% survival compared to 16% in the once-daily arm (p=0.04), along with better local control. However, the twice-daily regimen was associated with a higher incidence of grade 3 esophagitis (32% versus 16%). This trial established BID 45 Gy in 30 fractions as the standard radiation regimen for LS-SCLC. A common criticism of the study is that the once-daily arm used a relatively low total dose of 45 Gy, which may not represent an optimal once-daily regimen, thus limiting the fairness of the comparison.

CONVERT Trial (Faivre-Finn et al., 2017)

The CONVERT trial was a phase III study comparing the twice-daily regimen of 45 Gy in 30 fractions (1.5 Gy BID over 3 weeks) with a once-daily regimen of 66 Gy in 33 fractions (2 Gy per fraction over 6.5 weeks), both given concurrently with cisplatin and etoposide. The primary endpoint was 2-year OS. The results showed no statistically significant difference in 2-year OS between the two arms (56% for BID versus 51% for once-daily, p=0.14). Median OS was 30 months for the BID arm and 25 months for the once-daily arm. Rates of grade 3-4 esophagitis and neutropenia were similar between the groups. The trial concluded that both regimens are acceptable standards of care, with BID potentially offering a slight advantage, though the study was not powered to detect small differences.

CALGB 30610/RTOG 0538 (Bogart et al., 2023)

This phase III trial compared the standard 45 Gy BID regimen with a higher-dose once-daily regimen of 70 Gy in 35 fractions (2 Gy per fraction). An additional arm delivering 61.2 Gy with a concomitant boost was closed early due to futility. The 2-year OS was 56% for the BID arm and 54% for the once-daily 70 Gy arm, with no significant difference between them. These results confirmed that higher-dose once-daily radiation is a reasonable alternative to BID radiation, particularly for patients who cannot tolerate the logistical demands of twice-daily treatment.

Radiation Therapy Technique

Dose-Fractionation Options

The twice-daily regimen consists of 45 Gy delivered in 30 fractions of 1.5 Gy each, administered twice daily with at least a 6-hour interval between fractions, over a period of 3 weeks. Once-daily regimens include 66 Gy in 33 fractions, as used in the CONVERT trial, or 70 Gy in 35 fractions, as in CALGB 30610, delivered over 6.5 to 7 weeks. A once-daily regimen of 60 Gy in 30 fractions is also commonly used in clinical practice, although it has not been specifically validated in phase III trials.

Timing of Radiation

Early concurrent radiation, initiated with the first or second cycle of chemotherapy, has been shown to be superior to late or sequential radiation. Meta-analyses by Fried et al. and De Ruysscher et al. have demonstrated that starting radiation therapy within 30 days of chemotherapy initiation improves overall survival. Additionally, a short start-to-end radiation (SER) interval of 30 days or less is associated with the best outcomes.

Target Volume Delineation

Gross tumor volume (GTV) is defined as the visible tumor on CT and PET-CT imaging. When radiation begins after the first or second chemotherapy cycle, post-chemotherapy tumor volumes may be used. The choice between pre-chemotherapy and post-chemotherapy volumes remains controversial. However, the National Comprehensive Cancer Network (NCCN) and most guidelines recommend treating the post-chemotherapy tumor volume while including the pre-chemotherapy involved nodal stations. Uninvolved nodal stations that are visible only on pre-chemotherapy imaging may be omitted from the clinical target volume (CTV). The CTV is created by adding a 5-8 mm margin around the GTV and including the initially involved nodal stations. Elective nodal irradiation is not recommended in the era of involved-field radiation therapy (IFRT); PET-guided IFRT is the standard approach. The planning target volume (PTV) is generated by adding a 5-10 mm margin to the CTV, depending on image-guided radiation therapy (IGRT) capabilities and motion management.

Organs at Risk (OAR) Constraints

Dose constraints for organs at risk in LS-SCLC are similar to those used in locally advanced non-small cell lung cancer (NSCLC). Lung constraints include a V20 (volume receiving 20 Gy) of 35% or less and a mean lung dose of 20 Gy or less. The esophagus requires particular attention, especially with the BID regimen, which is associated with higher rates of esophagitis; thus, mean esophageal dose and V60 (volume receiving 60 Gy) should be minimized. The spinal cord maximum dose should not exceed 45 Gy. Heart dose should be minimized following principles established in RTOG 0617.

Prophylactic Cranial Irradiation (PCI)

Rationale

The brain is the most common site of first relapse in SCLC, occurring in 40-60% of patients without PCI. A meta-analysis by Auperin et al. in 1999 demonstrated that PCI reduces the incidence of brain metastases and improves 3-year overall survival (20.7% versus 15.3%) in patients who achieve a complete or good partial response after chemoradiation. The standard PCI dose is 25 Gy delivered in 10 fractions.

Evolving Role with MRI Surveillance

The role of PCI is evolving with the advent of MRI surveillance. The Japanese JCOG0212 trial (Takahashi et al., 2017) randomized patients with limited-stage and extensive-stage SCLC to PCI versus observation with serial MRI surveillance. Although PCI reduced brain metastases, it did not improve overall survival, challenging the previously accepted OS benefit, especially in extensive-stage disease. For limited-stage SCLC, PCI remains recommended by the NCCN but is increasingly controversial. Some institutions offer MRI surveillance every three months as an alternative, particularly for patients concerned about neurocognitive toxicity. Hippocampal-avoidant PCI (HA-PCI) is under investigation as a strategy to reduce neurocognitive side effects while maintaining control of brain metastases.

Neurocognitive Effects of PCI

PCI is associated with neurocognitive side effects, including memory impairment, decline in executive function, and reduced processing speed. These effects are more pronounced in older patients. The NMDA receptor antagonist memantine has shown potential in mitigating neurocognitive decline, as studied in the NRG CC003 trial. Therefore, a thorough risk-benefit discussion with patients is essential when considering PCI.

Concurrent Chemotherapy

Standard Regimen

The standard chemotherapy regimen consists of cisplatin at 60-80 mg/m² on day 1 combined with etoposide at 100-120 mg/m² on days 1 to 3, or alternatively cisplatin at 25 mg/m² plus etoposide at 100 mg/m² on days 1 to 3. Four to six cycles are typically administered, with concurrent radiation therapy beginning during the first or second cycle. Carboplatin may be substituted for cisplatin in patients with renal insufficiency, hearing loss, or neuropathy.

Immunotherapy in LS-SCLC

The ADRIATIC trial, reported in 2024, evaluated consolidation durvalumab with or without tremelimumab following concurrent chemoradiation in LS-SCLC. Durvalumab consolidation improved both overall survival and progression-free survival compared to placebo. This represents a practice-changing development for LS-SCLC, paralleling the PACIFIC paradigm established in NSCLC, and is poised to become a new standard of care once incorporated into clinical guidelines.

<image>A comparison figure of the three major LS-SCLC radiation trials (Turrisi INT 0096, CONVERT, CALGB 30610). Each trial is shown as a horizontal timeline indicating the radiation schedule (BID vs. once-daily), total dose, fractionation, and treatment duration. Below each trial, Kaplan-Meier OS curves are shown with median OS and 2-year/5-year OS rates annotated. Key differences in esophagitis rates are noted.</image>

<image>A schematic timeline of the optimal LS-SCLC treatment sequence. Chemotherapy cycles (cisplatin/etoposide x 4-6) are shown as vertical bars. Concurrent thoracic radiation (starting with cycle 1 or 2) is shown as a horizontal bar spanning 3 weeks (BID) or 6.5-7 weeks (once-daily). After CRT completion, PCI (25 Gy/10 fx) is shown starting 3-6 weeks later. Consolidation durvalumab (ADRIATIC) is shown as extending for up to 24 months post-CRT. The SER (start to end of RT) target of <=30 days is highlighted.</image>

<image>An axial CT image showing target volume delineation for LS-SCLC with a right hilar mass and station 7 and 4R lymphadenopathy. The pre-chemotherapy GTV (dashed red line) is overlaid on the post-chemotherapy CT, showing volume reduction. The post-chemotherapy GTV (solid red line) is smaller but includes the originally involved nodal stations. The CTV (blue) expands 6 mm from the GTV, and the PTV (green) adds 5 mm. Bilateral lungs, heart, and esophagus are contoured as OARs.</image>

Key Clinical Pearls

Twice-daily radiation delivering 45 Gy in 30 fractions over 3 weeks remains the reference standard based on the Turrisi trial. However, the CONVERT and CALGB 30610 trials have established that once-daily higher-dose radiation (66-70 Gy) is an acceptable alternative with comparable outcomes. Initiating radiation early and concurrently with the first or second cycle of chemotherapy is crucial to maximize local control and survival, as delays beyond 30 days from chemotherapy initiation are detrimental. For target delineation, post-chemotherapy tumor volumes combined with pre-chemotherapy nodal stations are standard; treating the full pre-chemotherapy tumor extent unnecessarily increases lung and esophageal radiation doses. Although PCI reduces the risk of brain metastases, its overall survival benefit is increasingly questioned in the MRI surveillance era, necessitating individualized discussions about risks and benefits, particularly regarding neurocognitive toxicity. Finally, the ADRIATIC trial’s results with consolidation durvalumab represent a potential paradigm shift in LS-SCLC treatment, mirroring the transformative impact of immunotherapy in NSCLC.

References

• Turrisi AT 3rd et al. "Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide." N Engl J Med. 1999;340(4):265-271.
• Faivre-Finn C et al. "Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial." Lancet Oncol. 2017;18(8):1116-1125.
• Bogart JA et al. "High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538." J Clin Oncol. 2023;41(6):1078-1087.
• Auperin A et al. "Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission." N Engl J Med. 1999;341(7):476-484.
• Takahashi T et al. "Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial." Lancet Oncol. 2017;18(5):663-671.

Read this lecture as Markdown